Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-specific-processing protease 14 (USP14) is a major deubiquitinating enzyme (DUB) that reversibly associates with the 19S regulatory particle of the 26S proteasome. It plays a dual role in proteostasis by trimming ubiquitin chains from substrates to facilitate their entry into the proteasome or by inhibiting degradation through premature deubiquitination. USP14 is typically autoinhibited in its free form and becomes catalytically active only upon binding to the proteasome. In oncology, USP14 is frequently overexpressed and contributes to tumor progression by stabilizing oncogenic proteins and inhibiting apoptosis. Conversely, in neurodegenerative contexts, inhibiting USP14 has been shown to accelerate the clearance of misfolded proteins such as tau and ataxin-3. Consequently, USP14 has emerged as a significant therapeutic target, with small-molecule inhibitors like IU1 being developed to modulate protein turnover in various diseases.
Inhibition of deubiquitinating activity to accelerate proteasomal degradation of substrates or induce proteotoxic stress in cancer cells
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-specific-processing protease 14 (USP14).